Bloodless glucose monitor to enter trials this year
This article was originally published in Clinica
Clinical trials are due to begin later this year of a novel glucose monitoring product that its developer, MicroSense International, claims will combine the best features available in conventional finger-stick based methods with a cost-competitive, painless and blood-free system. MicroSense, a St Louis, Missouri-based privately held development stage company, believes that by eliminating the discomfort associated with blood glucose monitoring, patients will gain greater control over their insulin management and an associated decline in complications.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.